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Background
The E3 ubiquitin ligase cbl-b has been identified as an
important gatekeeper limiting T cell activation. Concor-
dantly, the immune system of cbl-b deficient mice can
effectively fight tumors, thereby validating cbl-b as an
excellent target to enhance anti-tumor immune activity.
We have recently shown in proof-of-concept experiments
that transfer of transiently cbl-b silenced murine T cells
had efficacy to enhance the anti-tumor immune response
in mouse models.
Methods
A design algorithm was used to screen for siRNAs that are
highly effective to silence cbl-b, and the optimized siRNA
was produced at a GMP manufacturer. PBMCs were iso-
lated from healthy donors or cancer patients, transfected
with siRNA by electroporation and immune cell pheno-
type and activation was determined by FACS and ELISA.
For enhancement of DC vaccination responses, PBMCs
were ex vivo silenced, and co-administrated with the DC
preparations intranodally to the cancer patient.
Results
We have established a highly efficient transfection proto-
col using a commercial electroporation device enabling us
to simultaneously transfect T, B, NK cells and monocytes
with minimal cell damage. Using this protocol, we have
identified a siRNA that was able to shut down cbl-b
expression for more than 7 days in stimulated human
T cells, resulting in strong enhancement of T cell activa-
tion, cytokine production and proliferation. Moreover,
simultaneous silencing of cbl-b in all immune cells of the
PBMCs yielded additional advantages, most notably
enhancing NK cell reactivity against tumor cell and IL-2
stimulation. Silencing of cancer patient PBMCs yielded
similar results ex vivo and intranodal transfer of autolo-
gous cbl-b silenced cells together with activated DCs to
patients with advanced cancers was feasible and well
tolerated.
Conclusions
To enable the clinical implementation of a cbl-b ex vivo
silencing treatment, we have established and tested a
protocol that can be easily performed on any clinical
unit that applies adoptive cell therapies to patients.
Based on these results, a Phase I trial for the systemic
administration of cbl-b silenced PBMCs to patients with
advanced cancers is presently being set up.
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